Valeant Pharma Raises Offer For Salix Pharma: What it Means For Mutual Fund Investors (VRX, SLXP)

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

Channels

Find the latest content and information here about the 2019 Charles Schwab Impact Conference.

Advisors

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

Valeant Pharma Raises Offer For Salix Pharma: What it Means For Mutual Fund Investors (VRX, SLXP)

Valeant Pharmaceuticals
On Monday morning, Valeant Pharmaceuticals announced that it has increased its bid for Salix Pharmaceuticals. Here’s what the deal means for mutual fund investors.

Inside the Deal

Canada-based Valeant Pharmaceuticals adjusted its deal to acquire Salix Pharmaceuticals to $173 per share, or $11.1 billion. Including debt, the deal is valued at $15.8 billion.

In the previous deal, Valeant offered to acquire the company for $158 per share, or $14.5 billion. The offer was increased after Endo International (ENDP) expressed interest in acquiring Salix for $175 per share, or $11 billion.

The adjusted deal has been approved by the Boards of Directors of both companies.

Valeant And It’s M&A Strategy

This transaction will be one of many for Valeant. The pharmaceutical giant has made over 100 transactions since 2008, including joint ventures. M&A is a common strategy among many drug companies, as many struggle to grow organically without acquisitions.

Last year, Valeant’s deal to acquire Allergan (AGN) fell through, and since then, VRX has been seeking alternative deals.

Mutual Funds to Watch

Investors interested in VRX and may also consider a mutual fund as an alternative to owning the individual stock. The funds below currently hold the largest stakes in VRX.

The Bottom Line

The funds above are a great way for investors to gain exposure to a diverse bundle of securities and industries. Investors interested in VRX may also be interested in Allergan (AGN) and GlaxoSmithKline (GSK).

If you’ve enjoyed this article, sign up for the free MutualFunds.com newsletter; we’ll send you similar content weekly.


Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Popular Articles

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.


Read Next

Valeant Pharmaceuticals

Valeant Pharma Raises Offer For Salix Pharma: What it Means For Mutual Fund Investors (VRX, SLXP)

On Monday morning, Valeant Pharmaceuticals announced that it has increased its bid for Salix Pharmaceuticals. Here’s what the deal means for mutual fund investors.

Inside the Deal

Canada-based Valeant Pharmaceuticals adjusted its deal to acquire Salix Pharmaceuticals to $173 per share, or $11.1 billion. Including debt, the deal is valued at $15.8 billion.

In the previous deal, Valeant offered to acquire the company for $158 per share, or $14.5 billion. The offer was increased after Endo International (ENDP) expressed interest in acquiring Salix for $175 per share, or $11 billion.

The adjusted deal has been approved by the Boards of Directors of both companies.

Valeant And It’s M&A Strategy

This transaction will be one of many for Valeant. The pharmaceutical giant has made over 100 transactions since 2008, including joint ventures. M&A is a common strategy among many drug companies, as many struggle to grow organically without acquisitions.

Last year, Valeant’s deal to acquire Allergan (AGN) fell through, and since then, VRX has been seeking alternative deals.

Mutual Funds to Watch

Investors interested in VRX and may also consider a mutual fund as an alternative to owning the individual stock. The funds below currently hold the largest stakes in VRX.

The Bottom Line

The funds above are a great way for investors to gain exposure to a diverse bundle of securities and industries. Investors interested in VRX may also be interested in Allergan (AGN) and GlaxoSmithKline (GSK).

If you’ve enjoyed this article, sign up for the free MutualFunds.com newsletter; we’ll send you similar content weekly.


Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Popular Articles

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.


Read Next